Biosyent Inc
XTSX:RX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Biosyent Inc
XTSX:RX
|
CA |
|
Lovisa Holdings Ltd
F:LO7
|
AU |
|
Broadmedia Corp
TSE:4347
|
JP |
|
Francotyp Postalia Holding AG
F:FPH
|
DE |
Wall St Price Targets
RX Price Targets Summary
Biosyent Inc
According to Wall Street analysts, the average 1-year price target for RX is 18.36 CAD with a low forecast of 18.18 CAD and a high forecast of 18.9 CAD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is RX's stock price target?
Price Target
18.36
CAD
According to Wall Street analysts, the average 1-year price target for RX is 18.36 CAD with a low forecast of 18.18 CAD and a high forecast of 18.9 CAD.
What is the Revenue forecast for Biosyent Inc?
Projected CAGR
29%
Over the last 14 years, the compound annual growth rate for Revenue has been 22%. The projected CAGR for the next 3 years is 29%.
What is the Gross Profit forecast for Biosyent Inc?
Projected CAGR
-9%
Over the last 14 years, the compound annual growth rate for Gross Profit has been 21%. The projected CAGR for the next 7 years is -9%.
What is the Operating Income forecast for Biosyent Inc?
Projected CAGR
-11%
Over the last 14 years, the compound annual growth rate for Operating Income has been 26%. The projected CAGR for the next 6 years is -11%.
What is the Pre-Tax Income forecast for Biosyent Inc?
Projected CAGR
-8%
Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been 27%. The projected CAGR for the next 9 years is -8%.
What is the Net Income forecast for Biosyent Inc?
Projected CAGR
-13%
Over the last 14 years, the compound annual growth rate for Net Income has been 24%. The projected CAGR for the next 6 years is -13%.
